Bone marrow is a complex organ responsible for the regulation of hematopoietic cell distribution throughout the human body. Patients receiving antineoplastic agents as a therapeutic intervention for hematologic malignancy often experience varying degrees of myelotoxicity. Antineoplastic agents cause hypocellularity in marrow resulting in a reduction in hematopoietic tissue activity and a corresponding decline in cell production. Quantifying the adverse effects on hematopoiesis is based on the properties of a single agent, the use of individual drugs within a combination chemotherapy regimen, and the course, or courses, of chemotherapy designed to treat cancer. The direct or indirect suppression of erythrocytes, granulocytes, and megakaryocytes has potential for multiple negative clinical consequences ranging from increased monitoring of blood counts to life-threatening infection and death. This review will provide an overview of the structure and function of competent adult bone marrow, describe the process of hematopoiesis, and characterize the myelotoxicities associated with common antineoplastic agents currently used in the treatment of cancer.
SmithC. Hematopoietic stem cells and hematopoiesis. Cancer Control. 2003;10(1):9–16.
2.
PortenoyRKItriLM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist. 1999;4(1):1–10.
3.
BodeyGPBuckleyMSatheYS. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–340.
4.
EltingLSRubensteinEBMartinCG. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137–1146.
5.
FliednerTMGraessleDPaulsenCReimersK. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm. 2002;17(4):405–426.
6.
GulatiGLAshtonJKHyunBH. Structure and function of the bone marrow and hematopoiesis. Hematol Oncol Clin North Am. 1988;2(4):495–511.
7.
HaysK. Physiology of normal bone marrow. Semin Oncol Nurs. 1990;6(1):3–8.
8.
LohrmannHPSchremlW. Cytotoxic drugs and the granulopoietic system. Recent Results Cancer Res. 1982;81:1–222.
9.
TravlosGS. Normal structure, function, and histology of the bone marrow. Toxicol Pathol. 2006;34(5):548–565.
FlemmingW. Zellsubstanz, Kern und Zelltheilung. Leipzig: F.C.W. Vogel; 1882.
12.
HillBTBasergaR. The cell cycle and its significance for cancer treatment. Cancer Treat Rev. 1975;2(3):159–175.
13.
ChabnerBARobertsTGJr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72.
14.
IvanchukSMRutkaJT. The cell cycle: accelerators, brakes, and checkpoints. Neurosurgery. 2004;54(3):692–699.
15.
ShahMASchwartzGK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001;7(8):2168–2181.
16.
VermeulenKVan BockstaeleDRBernemanZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131–149.
17.
HartwellLHWeinertTA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989;246(4930):629–634.
18.
ViettiTJValerioteFA. Conceptual basis for use of chemotherapeutic agents and their pharmacology. Pediatr Clin North Am. 1976;23(1):67–92.
19.
EvanGIVousdenKH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348.
20.
FliednerTM. The role of blood stem cells in hematopoietic cell renewal. Stem Cells. 1998;16(6):361–374.
21.
TannockIF. Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;49(2):335–355.
22.
ParchmentREGordonMGrieshaberCK. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol. 1998;9(4):357–364.
23.
RisitanoAMMaciejewskiJPSelleriC. Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. Curr Stem Cell Res Ther. 2007;2(1):39–52.
24.
ShenYNilssonSK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol. 2012;19(4):250–255.
25.
WalkleyCR. Erythropoiesis, anemia and the bone marrow microenvironment. Int J Hematol. 2011;93(1):10–13.
26.
GordonMY. Physiology and function of the haemopoietic microenvironment. Br J Haematol. 1994;86(2):241–243.
27.
BotnickLEHannonECHellmanS. Nature of the hemopoietic stem cell compartment and its proliferative potential. Blood Cells. 1979;5(2):195–210.
28.
HellmanSReinckeUBotnickL. Functional organization of the hematopoietic stem cell compartment: implications for cancer and its therapy. J Clin Oncol. 1983;1(4):277–284.
29.
SnoeckHW. Aging of the hematopoietic system. Curr Opin Hematol. 2013;20(4):355–361.
30.
KaneB. Cancer chemotherapy: teaching old drugs new tricks. Ann Intern Med. 2001;135(12):1107–1110.
31.
GaleRP. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol. 1985;13(suppl 16):3–7.
32.
VerschraegenCFNatelsonEAGiovanellaBC. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs. 1998;9(1):36–44.
33.
DaleDC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62(suppl 1):1–15.
34.
BennettCLDjulbegovicBNorrisLB. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368(12):1131–1139.
35.
TefferiA. Anemia in adults: a contemporary approach to diagnosis. Mayo Clin Proc. 2003;78(10):1274–1280.
36.
GroopmanJEItriLM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616–1634.
37.
LudwigHVan BelleSBarrett-LeeP. The European Cancer Anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–2306.
38.
ParameswaranRLunningMManthaS. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22(5):1217–1222.
39.
ConnorsT. Anticancer drug development: the way forward. Oncologist. 1996;1(3):180–181.
40.
GilaniSTKhanDAKhanFA. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak. 2012;22(2):101–104.
41.
Gutierrez-UrenaSMolinaJFGarciaCO. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39(2):272–276.
42.
BatchelorTCarsonKO'NeillA. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–1049.
43.
RubensteinJLGuptaNKMannisGN. How I treat CNS lymphomas. Blood. 2013;122(14):2318–2330.
44.
SkarinATZuckermanKSPitmanSW. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977;50(6):1039–1047.
45.
GiaiMBigliaNSismondiP. Chemoresistance in breast tumors. Eur J Gynaecol Oncol. 1991;12(5):359–373.
46.
AscheleCSobreroAFaderanMA. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992;52(7):1855–1864.
SobreroAFAscheleCBertinoJR. Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997;15(1):368–381.
50.
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol. 1998;16(1):301–308.
51.
SeifertPBakerLHReedML. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975;36(1):123–128.
52.
. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-analysis group in cancer. J Clin Oncol. 1998;16(11):3537–3541.
53.
DeWysWDGoldinAManElN. Hematopoietic recovery after large doses of cyclophosphamide: correlation of proliferative state with sensitivity. Cancer Res. 1970;30(6):1692–1697.
54.
KatsumataNYasudaMTakahashiF. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–1338.
55.
BhuyanBKScheidtLGFraserTJ. Cell cycle phase specificity of antitumor agents. Cancer Res. 1972;32(2):398–407.
56.
MindermanHLinssenPvan der LelyN. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia. 1994;8(3):382–387.
57.
BergsagelDERobertsonGLHasselbackR. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. Can Med Assoc J. 1968;98(11):532–538.
58.
ScheinPSWinokurSH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med. 1975;82(1):84–95.
59.
TrainorKJSeshadriRSMorleyAA. Residual marrow injury following cytotoxic drugs. Leuk Res. 1979;3(4):205–210.
60.
LohrmannHP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984;41(3):180–184.
